Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.80 |
| ▸ | DPP4 | P27487 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.74 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.74 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.74 |
| ▸ | GAPDH | P04406 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.74 |
| ▸ | STAT6 | P42226 | 1/20 | 0.74 |
| ▸ | PI4KA | P42356 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.74 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.74 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.74 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6901255 | 1.00 | DOT1L (0.80) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL952929 | 1.00 | DOT1L (0.80) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL19111327 | 0.90 | AMD1 (0.80) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL17859778 | 0.90 | DOT1L (0.75) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL16202796 | 0.89 | DOT1L (1.00) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL27839942 | 0.88 | ADORA3 (0.91) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL13986400 | 0.88 | AMD1 (0.80) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL954272 | 0.88 | AMD1 (0.80) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL954273 | 0.88 | AMD1 (0.80) | DOT1LDPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL16129513 | 0.88 | DOT1L (0.64) | DOT1LDPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2574616-A2 | 5'-substituted adenosynes, preparation thereof and use as inhibitors of s-adenosylmethionine decarboxylase. | Southern Research Institute (US) | 2013-04-03 | — | — | EP | claimed |
| US-20110009354-A1 | 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | claimed |
| EP-2170057-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | Southern Research Institute (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009018541-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | SOUTHERN RESEARCH INSTITUTE (US) | 2009-02-05 | — | — | WO | claimed |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-05-18 | — | — | US | disclosed |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-05-18 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-9446064-B2 | Combination therapy for treating cancer | Epizyme, Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| US-8637485-B2 | 5′,-substituted adenosynes preparation thereof and use as inhibitors of S-adenosylmethionine decarboxylase | SOUTHERN RESEARCH INSTITUTE (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2574616-A2 | 5'-substituted adenosynes, preparation thereof and use as inhibitors of s-adenosylmethionine decarboxylase. | Southern Research Institute (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20110009354-A1 | 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| EP-2170057-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | Southern Research Institute (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009018541-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | SOUTHERN RESEARCH INSTITUTE (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1482977-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003074083-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | DOT1L 1/4885DPP4 3127/4885MEN1 2681/4885 |
| US-20110009354-A1 | 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | AMD1, ADA, MTAP | DOT1L 363/4885DPP4 3433/4885MEN1 2040/4885 |
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | DOT1L, CARM1, MCL1 | DOT1L 1/4885DPP4 3797/4885MEN1 3936/4885 |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | DOT1L 1/4885DPP4 3127/4885MEN1 2681/4885 |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | DOT1L 1/4885DPP4 3061/4885MEN1 3138/4885 |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | DOT1L 6/4885DPP4 1847/4885MEN1 3299/4885 |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | DOT1L 1250/4885DPP4 1351/4885MEN1 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.